What is DxTerity?
DxTerity operates at the intersection of biotechnology and precision medicine, specializing in the development of RNA-based diagnostic tools for autoimmune diseases. The company distinguishes itself through a proprietary technology platform that facilitates affordable, at-home genomic monitoring, effectively decentralizing complex diagnostic processes. By providing healthcare providers with granular biological insights, DxTerity empowers a more personalized approach to disease management. Their market position is defined by a commitment to lowering the cost of high-fidelity testing, thereby increasing accessibility to advanced genomic data. This focus on clinical utility and patient-centric care has established the firm as a key innovator in the autoimmune diagnostic landscape, where precision and speed are paramount for improving long-term patient outcomes.
How much funding has DxTerity raised?
DxTerity has raised a total of $4.5M across 4 funding rounds:
Private Equity
$790K
Debt
$2.6M
Debt
$350K
Debt
$794K
Private Equity (2009): $790K, investors not publicly disclosed
Debt (2012): $2.6M, investors not publicly disclosed
Debt (2020): $350K supported by PPP
Debt (2021): $794K featuring PPP
Key Investors in DxTerity
PPP
Public-Private Partnership
Undisclosed Investor
An institutional backer focused on long-term value creation and scaling high-potential biotechnology enterprises.
Undisclosed Investor
A credit-focused partner providing the necessary liquidity to support operational expansion and research development.
What's next for DxTerity?
With the recent influx of capital, DxTerity is well-positioned to accelerate its clinical study pipeline and expand its diagnostic portfolio. The strategic focus will likely shift toward scaling the commercial deployment of its at-home monitoring kits and deepening its integration into existing healthcare provider workflows. As the company matures, the emphasis will remain on validating its RNA-based markers across a broader spectrum of autoimmune conditions, potentially opening new revenue streams in chronic disease management. Future growth will be driven by the continued refinement of its patented technology, ensuring that DxTerity remains at the forefront of the precision medicine revolution while maintaining its core mission of cost-effective, accessible diagnostic excellence.
See full DxTerity company page
